{"id":781616,"date":"2026-05-08T09:06:14","date_gmt":"2026-05-08T09:06:14","guid":{"rendered":"https:\/\/www.europesays.com\/us\/781616\/"},"modified":"2026-05-08T09:06:14","modified_gmt":"2026-05-08T09:06:14","slug":"doctors-warn-against-using-fake-drug-for-weight-loss-nbc-connecticut","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/781616\/","title":{"rendered":"Doctors warn against using fake drug for weight loss \u2013 NBC Connecticut"},"content":{"rendered":"<p>Weight loss drugs are almost everywhere you look, and a new one that could give you results faster might soon hit the market, but some companies are already selling it, even without FDA approval.<\/p>\n<p>An experimental drug called <a href=\"https:\/\/www.lilly.com\/news\/stories\/what-to-know-about-retatrutide\" rel=\"nofollow noopener\" target=\"_blank\">retatrutide<\/a>, also known as reta or Triple-G, is in a pharmaceutical company Eli Lilly-sponsored clinical trials. Retatrutide is an injection administered once weekly that mimics hormones that suppress hunger.<\/p>\n<p>Retatrutide is not publicly available since it&#8217;s still being tested in clinical trials. <\/p>\n<p>Eli Lilly is in phase 3 of those trials, testing retatrutide for obesity, type 2 diabetes, knee\u00a0osteoarthritis\u00a0pain,\u00a0moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated\u00a0steatotic\u00a0liver disease, according to the company&#8217;s website.<\/p>\n<p>Phase 2 clinical trial results were released in 2023. People lost on average 24% of their body weight, about 58 pounds in 48 weeks, which seems to be faster than other weight loss drugs, according to <a href=\"https:\/\/www.nbcnews.com\/health\/health-news\/experimental-drug-offer-weight-loss-drug-now-market-study-finds-rcna89702\" rel=\"nofollow noopener\" target=\"_blank\">a report by NBC News.<\/a><\/p>\n<p>Even though retatrutide is still being tested, at least 10 companies were selling it online. The FDA sent warning letters to those companies for selling unapproved and misbranded drugs.<\/p>\n<p>Dr. Mohit Chatpar, who is board-certified in obesity medicine, said it\u2019s very dangerous to use medication that is not federally approved because you don\u2019t know exactly what you\u2019re getting.<\/p>\n<p>\u201cIt could be more or less of a compound or an ingredient, it could be contaminated,&#8221; he said. &#8220;Maybe it wasn&#8217;t sterile or stored properly. It&#8217;s really important for injectable medications to make sure that it&#8217;s actually sterile. It&#8217;s stored properly. You&#8217;re putting something directly into the body. You&#8217;re bypassing the gut so you want to make sure it&#8217;s the proper medication that you should be taking.&#8221;<\/p>\n<p>The drugs approved for weight loss, such as Zepbound and Wegovy, have undergone rigorous testing and trials, according to Chatpar.<\/p>\n<p>More results from retatrutide clinical trials are expected over the next year, and the drug would need FDA approval before it hits the market.<\/p>\n","protected":false},"excerpt":{"rendered":"Weight loss drugs are almost everywhere you look, and a new one that could give you results faster&hellip;\n","protected":false},"author":3,"featured_media":781617,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[210,1060,67,132,68],"class_list":{"0":"post-781616","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-health","9":"tag-medication","10":"tag-united-states","11":"tag-unitedstates","12":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116538165681798852","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/781616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=781616"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/781616\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/781617"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=781616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=781616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=781616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}